Alliance A021806 is a Phase III trial that aims to evaluate the efficacy of perioperative chemotherapy with mFOLFIRINOX in patients with resectable pancreatic cancer.1, 2 The study is actively accruing randomized controlled phase III trial evaluating the efficacy of perioperative chemotherapy with mFOLFIRINOX in patients with resectable pancreatic cancer.3,4 The trial opened to accrual in July 2020 and plans to enroll 353 patients with resectable pancreatic cancer from the US and Canada.1
The study team will randomize patients to treatment with perioperative mFOLFIRINOX (perioperative arm) or upfront surgery followed by postoperative mFOLFIRINOX (adjuvant arm).1 Patients randomized to the perioperative arm undergo eight cycles of neoadjuvant mFOLFIRINOX followed by a curative-intent resection. These patients then will receive four additional cycles of mFOLFIRINOX in the postoperative setting. Patients randomized to the adjuvant arm undergo 12 cycles of adjuvant mFOLFIRINOX following pancreatectomy.1
1 https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/july-2022-volume-107-number-7/alliance-a021806-a-phase-iii-trial-of-perioperative-vs-adjuvant-chemotherapy-for-resectable-pancreatic-cancer/
2 https://bulletin.facs.org/2020/10/alliance-a021806-examines-perioperative-vs-adjuvant-chemotherapy-for-resectable-pancreatic-cancer/
3 https://meetings.asco.org/abstracts-presentations/225889
4 https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.TPS4204